Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551782890> ?p ?o ?g. }
- W1551782890 endingPage "1676" @default.
- W1551782890 startingPage "1674" @default.
- W1551782890 abstract "Two novel neuroprotective cholinesterase (ChE) inhibitors, TV3326, (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate, and TV3279, (N-propargyl-(3S) aminoindan-5-yl)-ethyl methyl carbamate, were derived from rasagiline for the treatment of Alzheimer's disease (AD). TV3326 also inhibits monoamine oxidase (MAO)-A and -B, whereas its S-isomer, TV3279, lacks MAO inhibitory activity. The action of these drugs in the regulation of amyloid precursor protein (APP) processing, using rat PC12 and human SH-SY5Y neuroblastoma cells, was examined. Both isomers stimulated the release of the non-amyloidogenic a-secretase form of soluble APP (sAPPalpha) from these cell lines. The increases in sAPPalpha, induced by TV3326 and TV3279, were dose-dependent (0.1-100 mM) and blocked by the hydroxamic acid-based metalloprotease inhibitor, Ro31-9790, suggesting mediation via a-secretase activity. Using several signal transduction inhibitors, we identified the involvement of protein kinase C (PKC), mitogen-activated protein (MAP) kinase, and tyrosine kinase-dependent pathways in the enhancement of sAPPalpha release by TV3326 and TV3279. In addition, both drugs directly induced the phosphorylation of p44 and p42 MAP kinase, which was abolished by the specific inhibitors of MAP kinase activation, PD98059 and U0126. These data suggest a novel pharmacological mechanism whereby these ChE inhibitors regulate the secretory processes of APP via activation of the MAP kinase pathway." @default.
- W1551782890 created "2016-06-24" @default.
- W1551782890 creator A5000909905 @default.
- W1551782890 creator A5005030965 @default.
- W1551782890 creator A5012715564 @default.
- W1551782890 creator A5053858269 @default.
- W1551782890 creator A5089887580 @default.
- W1551782890 date "2002-08-21" @default.
- W1551782890 modified "2023-09-24" @default.
- W1551782890 title "The involvement of mitogen‐activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline" @default.
- W1551782890 cites W120263029 @default.
- W1551782890 cites W1480173187 @default.
- W1551782890 cites W1524643915 @default.
- W1551782890 cites W1563482732 @default.
- W1551782890 cites W1580230845 @default.
- W1551782890 cites W1762207349 @default.
- W1551782890 cites W1782613870 @default.
- W1551782890 cites W1794943105 @default.
- W1551782890 cites W1964972074 @default.
- W1551782890 cites W1971915141 @default.
- W1551782890 cites W1979543098 @default.
- W1551782890 cites W1980433009 @default.
- W1551782890 cites W1980749733 @default.
- W1551782890 cites W1981657815 @default.
- W1551782890 cites W1983614213 @default.
- W1551782890 cites W1985722204 @default.
- W1551782890 cites W1988151367 @default.
- W1551782890 cites W1990543766 @default.
- W1551782890 cites W1993964261 @default.
- W1551782890 cites W1995650022 @default.
- W1551782890 cites W2004436319 @default.
- W1551782890 cites W2005056819 @default.
- W1551782890 cites W2007158999 @default.
- W1551782890 cites W2007812909 @default.
- W1551782890 cites W2009389965 @default.
- W1551782890 cites W2010170013 @default.
- W1551782890 cites W2016777985 @default.
- W1551782890 cites W2018733967 @default.
- W1551782890 cites W2019500453 @default.
- W1551782890 cites W2024452707 @default.
- W1551782890 cites W2024673430 @default.
- W1551782890 cites W2026547060 @default.
- W1551782890 cites W2033033457 @default.
- W1551782890 cites W2033382511 @default.
- W1551782890 cites W2033592766 @default.
- W1551782890 cites W2037204745 @default.
- W1551782890 cites W2038012168 @default.
- W1551782890 cites W2044949903 @default.
- W1551782890 cites W2047694858 @default.
- W1551782890 cites W2048302866 @default.
- W1551782890 cites W2054883386 @default.
- W1551782890 cites W2056181922 @default.
- W1551782890 cites W2057005933 @default.
- W1551782890 cites W2059340004 @default.
- W1551782890 cites W2059865238 @default.
- W1551782890 cites W2061014101 @default.
- W1551782890 cites W2062784484 @default.
- W1551782890 cites W2064097612 @default.
- W1551782890 cites W2070887142 @default.
- W1551782890 cites W2071691905 @default.
- W1551782890 cites W2074124665 @default.
- W1551782890 cites W2074866899 @default.
- W1551782890 cites W2077474349 @default.
- W1551782890 cites W2077582701 @default.
- W1551782890 cites W2081881251 @default.
- W1551782890 cites W2082953267 @default.
- W1551782890 cites W2084962301 @default.
- W1551782890 cites W2086262311 @default.
- W1551782890 cites W2090150925 @default.
- W1551782890 cites W2090496922 @default.
- W1551782890 cites W2090737341 @default.
- W1551782890 cites W2091558615 @default.
- W1551782890 cites W2099700886 @default.
- W1551782890 cites W2101077392 @default.
- W1551782890 cites W2113434206 @default.
- W1551782890 cites W2118977349 @default.
- W1551782890 cites W2136697740 @default.
- W1551782890 cites W2166507033 @default.
- W1551782890 cites W2171607869 @default.
- W1551782890 cites W2302113434 @default.
- W1551782890 cites W2335721464 @default.
- W1551782890 doi "https://doi.org/10.1096/fj.02-0198fje" @default.
- W1551782890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12206996" @default.
- W1551782890 hasPublicationYear "2002" @default.
- W1551782890 type Work @default.
- W1551782890 sameAs 1551782890 @default.
- W1551782890 citedByCount "101" @default.
- W1551782890 countsByYear W15517828902012 @default.
- W1551782890 countsByYear W15517828902013 @default.
- W1551782890 countsByYear W15517828902014 @default.
- W1551782890 countsByYear W15517828902015 @default.
- W1551782890 countsByYear W15517828902016 @default.
- W1551782890 countsByYear W15517828902017 @default.
- W1551782890 countsByYear W15517828902020 @default.
- W1551782890 countsByYear W15517828902021 @default.
- W1551782890 countsByYear W15517828902022 @default.
- W1551782890 countsByYear W15517828902023 @default.
- W1551782890 crossrefType "journal-article" @default.